Directing dendritic cell immunotherapy towards successful cancer treatment

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Banchereau J, Briere F, Caux C et al.: Immunobiology of dendritic cells. Annu. Rev. Immunol.18,767–811 (2000).
  Medline CASGoogle Scholar
• 2  Naik SH, Sathe P, Park HY et al.: Development of plasmacytoid and conventional dendritic cell subtypes from single precursor cells derived in vitro and in vivo. Nat. Immunol.8(11),1217–1226 (2007).
  Medline CASGoogle Scholar
• 3  Mckenna K, Beignon AS, Bhardwaj N: Plasmacytoid dendritic cells: linking innate and adaptive immunity. J. Virol.79(1),17–27 (2005).
  Medline CASGoogle Scholar
• 4  Salio M, Cella M, Vermi W et al.: Plasmacytoid dendritic cells prime IFN-γ-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur. J, Immunol,33(4),1052–1062 (2003).
  Medline CASGoogle Scholar
• 5  Hartmann E, Wollenberg B, Rothenfusser S et al.: Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res.63(19),6478–6487 (2003).
  Medline CASGoogle Scholar
• 6  Dunn GP, Bruce AT, Sheehan KC et al.: A critical function for type I interferons in cancer immunoediting. Nat. Immunol.6(7),722–729 (2005).
  Medline CASGoogle Scholar
• 7  Gerlini G, Urso C, Mariotti G et al.: Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes. Clin. Immunol.125(2),184–193 (2007).
  Medline CASGoogle Scholar
• 8  Battaglia A, Buzzonetti A, Baranello C et al.: Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer. Cancer Immunol. Immunother.58(9),1363–1373 (2009).
  MedlineGoogle Scholar
• 9  Sharma MD, Baban B, Chandler P et al.: Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature tregs via indoleamine 2,3-dioxygenase. J. Clin. Invest.117(9),2570–2582 (2007).
  Medline CASGoogle Scholar
• 10  Munn Dh, Sharma Md, Hou D et al.: Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest.114(2),280–290 (2004).
  Medline CASGoogle Scholar
• 11  Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol.3(2),133–146 (2003).
  Medline CASGoogle Scholar
• 12  Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S: Antigen presentation and T-cell stimulation by dendritic cells. Annu. Rev. Immunol.20,621–667 (2002).
  Medline CASGoogle Scholar
• 13  Mori L, De Libero G: Presentation of lipid antigens to T cells. Immunol. Lett.117(1),1–8 (2008).
  Medline CASGoogle Scholar
• 14  Ishikawa A, Motohashi S, Ishikawa Eet al.: A Phase I study of α-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res.11(5),1910–1917 (2005).
  Medline CASGoogle Scholar
• 15  Seino K, Motohashi S, Fujisawa T, Nakayama T, Taniguchi M: Natural killer T cell-mediated anti-tumor immune responses and their clinical applications. Cancer Sci.97(9),807–812 (2006).
  Medline CASGoogle Scholar
• 16  Cambi A, Koopman M, Figdor CG: How C-type lectins detect pathogens. Cell. Microbiol7(4),481–488 (2005).
  Medline CASGoogle Scholar
• 17  Van Vliet SJ, Garcia-Vallejo JJ, Van Kooyk Y: Dendritic cells and C-type lectin receptors: coupling innate to adaptive immune responses. Immunol. Cell. Biol.86(7),580–587 (2008).
  Medline CASGoogle Scholar
• 18  Tacken PJ, De Vries IJ, Torensma R, Figdor CG: Dendritic-cell immunotherapy: From ex vivo loading to in vivo targeting. Nat. Rev. Immunol.7(10),790–802 (2007).
  Medline CASGoogle Scholar
• 19  Tacken PJ, De Vries IJ, Gijzen K et al.: Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood106(4),1278–1285 (2005).
  Medline CASGoogle Scholar
• 20  Bonifaz LC, Bonnyay DP, Charalambous A et al.: in vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T-cell vaccination. J. Exp. Med.199(6),815–824 (2004).
  Medline CASGoogle Scholar
• 21  Smith AL, Ganesh L, Leung K,Jongstra-Bilen J, Jongstra J, Nabel GJ: Leukocyte-specific protein 1 interacts with DC-SIGN and mediates transport of HIV to the proteasome in dendritic cells. J. Exp. Med.204(2),421–430 (2007).
  Medline CASGoogle Scholar
• 22  Akira S, Takeda K: Toll-like receptor signalling. Nat. Rev. Immunol.4(7),499–511 (2004).
  Medline CASGoogle Scholar
• 23  Kato H, Takeuchi O, Sato S et al.: Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature441(7089),101–105 (2006).
  Medline CASGoogle Scholar
• 24  Pedra JH, Cassel SL, Sutterwala FS: Sensing pathogens and danger signals by the inflammasome. Curr. Opin. Immunol.21(1),10–16 (2009).
  Medline CASGoogle Scholar
• 25  Skoberne M, Beignon AS, Bhardwaj N: Danger signals: a time and space continuum. Trends Mol. Med.10(6),251–257 (2004).
  Medline CASGoogle Scholar
• 26  Martin-Fontecha A, Lanzavecchia A, Sallusto F: Dendritic cell migration to peripheral lymph nodes. Handb. Exp. Pharmacol. (188),31–49 (2009).
  MedlineGoogle Scholar
• 27  Scholer A, Hugues S, Boissonnas A, Fetler L, Amigorena S: Intercellular adhesion molecule-1-dependent stable interactions between T cells and dendritic cells determine CD8⁺ T-cell memory. Immunity28(2),258–270 (2008).
  Medline CASGoogle Scholar
• 28  Peggs KS, Quezada SA, Allison JP: Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol. Rev.224,141–165 (2008).
  Medline CASGoogle Scholar
• 29  Elgueta R, Benson MJ, De Vries VC, Wasiuk A, Guo Y, Noelle RJ: Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol. Rev.229(1),152–172 (2009).
  Medline CASGoogle Scholar
• 30  Sallusto F, Lanzavecchia A: Human Th17 cells in infection and autoimmunity. Microbes Infect.11(5),620–624 (2009).
  Medline CASGoogle Scholar
• 31  Tang Q, Bluestone JA: The 3⁺ regulatory T cell: a jack of all trades, master of regulation. Nat. Immunol.9(3),239–244 (2008).
  Medline CASGoogle Scholar
• 32  Sokol CL, Chu NQ, Yu S, Nish SA, Laufer TM, Medzhitov R: Basophils function as antigen-presenting cells for an allergen-induced T helper type 2 response. Nat. Immunol.10(7),713–720 (2009).
  Medline CASGoogle Scholar
• 33  Ito T, Wang YH, Duramad O et al.: TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J. Exp. Med.202(9),1213–1223 (2005).
  Medline CASGoogle Scholar
• 34  Manel N, Unutmaz D, Littman DR: The differentiation of human Th-17 cells requires transforming growth factor-β and induction of the nuclear receptor ROR-γ-t. Nat. Immunol.9(6),641–649 (2008).
  Medline CASGoogle Scholar
• 35  Jego G, Pascual V, Palucka AK, Banchereau J: Dendritic cells control B-cell growth and differentiation. Curr. Dir. Autoimmun.8,124–139 (2005).
  Medline CASGoogle Scholar
• 36  Munz C, Dao T, Ferlazzo G, De Cos MA, Goodman K, Young JW: Mature myeloid dendritic cell subsets have distinct roles for activation and viability of circulating human natural killer cells. Blood105(1),266–273 (2005).
  MedlineGoogle Scholar
• 37  Fujii S, Shimizu K, Kronenberg M, Steinman RM: Prolonged IFN-γ-producing nkt response induced with α-galactosylceramide-loaded DCs. Nat. Immunol.3(9),867–874 (2002).
  Medline CASGoogle Scholar
• 38  Cools N, Ponsaerts P, Van Tendeloo VF, Berneman ZN: Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells. J. Leukoc. Biol.82(6),1365–1374 (2007).
  Medline CASGoogle Scholar
• 39  Mellor AL, Munn DH: IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol.4(10),762–774 (2004).
  Medline CASGoogle Scholar
• 40  Munn DH, Mellor AL: IDO and tolerance to tumors. Trends Mol. Med.10(1),15–18 (2004).
  Medline CASGoogle Scholar
• 41  Levings MK, Gregori S, Tresoldi E, Cazzaniga S, Bonini C, Roncarolo MG: Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25⁺CD4⁺ Tr cells. Blood105(3),1162–1169 (2005).
  Medline CASGoogle Scholar
• 42  Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH: Induction of interleukin 10-producing, nonproliferating CD4⁺ T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J. Exp. Med.192(9),1213–1222 (2000).
  Medline CASGoogle Scholar
• 43  Woo EY, Chu CS, Goletz TJ et al.: Regulatory CD4⁺CD25⁺ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res.61(12),4766–4772 (2001).
  Medline CASGoogle Scholar
• 44  Liyanage UK, Moore TT, Joo HG et al.: Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol.169(5),2756–2761 (2002).
  Medline CASGoogle Scholar
• 45  Viehl CT, Moore TT, Liyanage UK et al.: Depletion of CD4⁺CD25⁺ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice. Ann. Surg. Oncol.13(9),1252–1258 (2006).
  MedlineGoogle Scholar
• 46  Chen W, Liang X, Peterson AJ, Munn DH, Blazar BR: The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive t regulatory cell generation. J. Immunol.181(8),5396–5404 (2008).
  Medline CASGoogle Scholar
• 47  Skoberne M, Somersan S, Almodovar W et al.: The apoptotic-cell receptor CR3, but not αVβ5, is a regulator of human dendritic-cell immunostimulatory function. Blood108(3),947–955 (2006).
  Medline CASGoogle Scholar
• 48  Skoberne M, Beignon AS, Larsson M, Bhardwaj N: Apoptotic cells at the crossroads of tolerance and immunity. Curr. Top. Microbiol. Immunol.289,259–292 (2005).
  Medline CASGoogle Scholar
• 49  Satzger I, Schenck F, Kapp A, Gutzmer R: Spontaneous regression of melanoma with distant metastases – report of a patient with brain metastases. Eur. J. Dermatol.16(4),454–455 (2006).
  MedlineGoogle Scholar
• 50  Wang RF, Rosenberg SA: Human tumor antigens for cancer vaccine development. Immunol. Rev.170,85–100 (1999).
  Medline CASGoogle Scholar
• 51  Kim R, Emi M, Tanabe K: Cancer immunoediting from immune surveillance to immune escape. Immunology121(1),1–14 (2007).
  Medline CASGoogle Scholar
• 52  Smyth MJ, Dunn GP, Schreiber RD: Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv. Immunol.90,1–50 (2006).
  Medline CASGoogle Scholar
• 53  Gandhi RT, O’neill D, Bosch RJ et al.: A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. Canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine27(43),6088–6094 (2009).
  Medline CASGoogle Scholar
• 54  Palucka AK, Ueno H, Connolly J et al.: Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8⁺ T-cell immunity. J. Immunother.29(5),545–557 (2006).
  Medline CASGoogle Scholar
• 55  Redman BG, Chang AE, Whitfield J et al.: Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma. J. Immunother.31(6),591–598 (2008).
  Medline CASGoogle Scholar
• 56  O’neill DW, Bhardwaj N: Differentiation of peripheral blood monocytes into dendritic cells. Curr. Protoc. Immunol. Chapter 22, Unit 22F 4 (2005).
  MedlineGoogle Scholar
• 57  O’neill D, Bhardwaj N: Generation of autologous peptide- and protein-pulsed dendritic cells for patient-specific immunotherapy. Methods Mol. Med.109,97–112 (2005).▪ Standardized protocol for generating antigen-pulsed dendritic cells (DCs)for immunotherapy.
  MedlineGoogle Scholar
• 58  Obermaier B, Dauer M, Herten J, Schad K, Endres S, Eigler A: Development of a new protocol for 2-day generation of mature dendritic cells from human monocytes. Biol. Proced. Online5,197–203 (2003).
  Medline CASGoogle Scholar
• 59  Dauer M, Obermaier B, Herten J et al.: Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J. Immunol.170(8),4069–4076 (2003).
  Medline CASGoogle Scholar
• 60  Alldawi L, Takahashi M, Narita M et al.: Effect of prostaglandin E2, lipopolysaccharide, IFN-γ and cytokines on the generation and function of fast-DC. Cytotherapy7(2),195–202 (2005).
  Medline CASGoogle Scholar
• 61  Jarnjak-Jankovic S, Hammerstad H, Saeboe-Larssen S, Kvalheim G, Gaudernack G: A full scale comparative study of methods for generation of functional dendritic cells for use as cancer vaccines. BMC Cancer7,119 (2007).
  MedlineGoogle Scholar
• 62  Banchereau J, Palucka AK, Dhodapkar M et al.: Immune and clinical responses in patients with metastatic melanoma to CD34⁺ progenitor-derived dendritic cell vaccine. Cancer Res.61(17),6451–6458 (2001).
  Medline CASGoogle Scholar
• 63  Klechevsky E, Liu M, Morita R et al.: Understanding human myeloid dendritic cell subsets for the rational design of novel vaccines. Hum. Immunol.70(5),281–288 (2009).
  Medline CASGoogle Scholar
• 64  Fay JW, Palucka AK, Paczesny S et al.: Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34⁺ progenitor-derived dendritic cells. Cancer Immunol. Immunotherapy55,1209–1218 (2006).
  Medline CASGoogle Scholar
• 65  Banchereau J, Ueno H, Dhodapkar M et al.: Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34⁺ progenitors and activated with type I interferon. J. Immunother.28,505–516 (2005).
  Medline CASGoogle Scholar
• 66  Marroquin CE, Westwood JA, Lapointe R et al.: Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cells. J. Immunother.25(3),278–288 (2002).
  Medline CASGoogle Scholar
• 67  Pulendran B, Banchereau J, Burkeholder S et al.: Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J. Immunol.165(1),566–572 (2000).
  Medline CASGoogle Scholar
• 68  Small EJ, Schellhammer PF, Higano CS et al.: Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol.24(19),3089–3094 (2006).
  Medline CASGoogle Scholar
• 69  Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N: Antigen-specific inhibition of effector T-cell function in humans after injection of immature dendritic cells. J. Exp. Med.193(2),233–238 (2001).▪ Mature DCs are required to activate appropriate T-cell responses.
  Medline CASGoogle Scholar
• 70  Dhodapkar MV, Steinman RM: Antigen-bearing immature dendritic cells induce peptide-specific CD8⁺ regulatory T cells in vivo in humans. Blood100(1),174–177 (2002).
  Medline CASGoogle Scholar
• 71  De Vries IJ, Lesterhuis WJ, Scharenborg NM et al.: Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin. Cancer Res.9(14),5091–5100 (2003).
  Medline CASGoogle Scholar
• 72  De Vries IJ, Krooshoop DJ, Scharenborg NM et al.: Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res.63(1),12–17 (2003).
  Medline CASGoogle Scholar
• 73  Lee AW, Truong T, Bickham K et al.: A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. Vaccine20(Suppl. 4),A8–A22 (2002).
  Medline CASGoogle Scholar
• 74  Jongmans W, Tiemessen DM, Van Vlodrop IJ, Mulders PF, Oosterwijk E: Th1-polarizing capacity of clinical-grade dendritic cells is triggered by ribomunyl but is compromised by PGE2: the importance of maturation cocktails. J. Immunother.28(5),480–487 (2005).
  Medline CASGoogle Scholar
• 75  Krause P, Singer E, Darley PI, Klebensberger J, Groettrup M, Legler DF: Prostaglandin E2 is a key factor for monocyte-derived dendritic cell maturation: enhanced T-cell stimulatory capacity despite IDO. J. Leukoc. Biol.82(5),1106–1114 (2007).
  Medline CASGoogle Scholar
• 76  Morelli AE, Thomson AW: Dendritic cells under the spell of prostaglandins. Trends Immunol.24(3),108–111 (2003).
  Medline CASGoogle Scholar
• 77  Scandella E, Men Y, Gillessen S, Forster R, Groettrup M: Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood100(4),1354–1361 (2002).
  Medline CASGoogle Scholar
• 78  Krause P, Bruckner M, Uermosi C, Singer E, Groettrup M, Legler DF: Prostaglandin E2 enhances T-cell proliferation by inducing the costimulatory molecules OX40L, CD70, and 4–1-βBL on dendritic cells. Blood113(11),2451–2460 (2009).
  Medline CASGoogle Scholar
• 79  Mailliard RB, Wankowicz-Kalinska A, Cai Q et al.: α-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res.64(17),5934–5937 (2004).
  Medline CASGoogle Scholar
• 80  Lee JJ, Foon KA, Mailliard RB, Muthuswamy R, Kalinski P: Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia. J. Leukoc. Biol.84(1),319–325 (2008).
  Medline CASGoogle Scholar
• 81  Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R: Toll-like receptorscontrol activation of adaptive immune responses. Nat. Immunol.2(10),947–950 (2001).
  Medline CASGoogle Scholar
• 82  Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A: Selected toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol.6(8),769–776 (2005).▪▪ Activation of selected combinations of Toll-like receptors on DCs results in synergistic effects on cytokine production of DCs.
  Medline CASGoogle Scholar
• 83  Boullart AC, Aarntzen EH, Verdijk P et al.: Maturation of monocyte-derived dendritic cells with toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration. Cancer Immunol. Immunother.57(11),1589–1597 (2008).
  Medline CASGoogle Scholar
• 84  Speetjens FM, Kuppen PJ, Welters MJ et al.: Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res15(3),1086–1095 (2009).
  Medline CASGoogle Scholar
• 85  Melief CJ, Van Der Burg SH: Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat. Rev. Cancer8(5),351–360 (2008).
  Medline CASGoogle Scholar
• 86  Barrou B, Benoit G, Ouldkaci M et al.: Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. Cancer Immunol. Immunother.53(5),453–460 (2004).
  MedlineGoogle Scholar
• 87  Salcedo M, Bercovici N, Taylor R et al.: Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol. Immunother.55(7),819–829 (2006).
  Medline CASGoogle Scholar
• 88  Mahdian R, Kokhaei P, Najar HM, Derkow K, Choudhury A, Mellstedt H: Dendritic cells, pulsed with lysate of allogeneic tumor cells, are capable of stimulating MHC-restricted antigen-specific anti-tumor T cells. Med. Oncol.23(2),273–282 (2006).
  Medline CASGoogle Scholar
• 89  Schnurr M, Galambos P, Scholz C et al.: Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Cancer Res.61(17),6445–6450 (2001).
  Medline CASGoogle Scholar
• 90  Thumann P, Moc I, Humrich J et al.: Antigen loading of dendritic cells with whole tumor cell preparations. J. Immunol. Methods277(1–2),1–16 (2003).
  Medline CASGoogle Scholar
• 91  Schnurr M, Chen Q, Shin A et al.: Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood105(6),2465–2472 (2005).
  Medline CASGoogle Scholar
• 92  Jenne L, Schuler G, Steinkasserer A: Viral vectors for dendritic cell-based immunotherapy. Trends Immunol.22(2),102–107 (2001).
  Medline CASGoogle Scholar
• 93  Brockstedt DG, Dubensky TW: Promises and challenges for the development of listeria monocytogenes-based immunotherapies. Expert Rev. Vaccines7(7),1069–1084 (2008).
  MedlineGoogle Scholar
• 94  Bellone S, El-Sahwi K, Cocco E et al.: Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8⁺ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8⁺CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines. J. Virol.83(13),6779–6789 (2009).
  Medline CASGoogle Scholar
• 95  Carrasco J, Van Pel A, Neyns B et al.: Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells. J. Immunol.180(5),3585–3593 (2008).
  Medline CASGoogle Scholar
• 96  Butterfield LH, Comin-Anduix B, Vujanovic L et al.: Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J. Immunother.31(3),294–309 (2008).
  MedlineGoogle Scholar
• 97  Veron P, Allo V, Riviere C, Bernard J, Douar AM, Masurier C: Major subsets of human dendritic cells are efficiently transduced by self-complementary adeno-associated virus vectors 1 and 2. J. Virol.81(10),5385–5394 (2007).
  Medline CASGoogle Scholar
• 98  Skoberne M, Yewdall A, Bahjat KS et al.: KBMA listeria monocytogenesis an effective vector for DC-mediated induction of anti-tumor immunity. J. Clin. Invest.118(12),3990–4001 (2008).
  Medline CASGoogle Scholar
• 99  Breckpot K, Aerts JL, Thielemans K: Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics. Gene Ther.14(11),847–862 (2007).
  Medline CASGoogle Scholar
• 100  He Y, Munn D, Falo LD Jr: Recombinant lentivector as a genetic immunization vehicle for anti-tumor immunity. Expert Rev. Vaccines6(6),913–924 (2007).
  Medline CASGoogle Scholar
• 101  Schroers R, Sinha I, Segall H et al.: Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system. Mol. Ther.1(2),171–179 (2000).
  Medline CASGoogle Scholar
• 102  Dyall J, Latouche JB, Schnell S, Sadelain M: Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes. Blood97(1),114–121 (2001).
  Medline CASGoogle Scholar
• 103  Lizee G, Gonzales MI, Topalian SL: Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells. Hum. Gene Ther.15(4),393–404 (2004).
  Medline CASGoogle Scholar
• 104  He Y, Zhang J, Mi Z, Robbins P, Falo LD Jr: Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T-cell responses and therapeutic immunity. J. Immunol.174(6),3808–3817 (2005).
  Medline CASGoogle Scholar
• 105  Dullaers M, Van Meirvenne S, Heirman C et al.: Induction of effective therapeutic anti-tumor immunity by direct in vivo administration of lentiviral vectors. Gene Ther.13(7),630–640 (2006).
  Medline CASGoogle Scholar
• 106  Breckpot K, Heirman C, De Greef C, Van Der Bruggen P, Thielemans K: Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses. J. Immunol.172(4),2232–2237 (2004).
  Medline CASGoogle Scholar
• 107  Yang L, Yang H, Rideout K et al.: Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat. Biotechnol.26(3),326–334 (2008).
  Medline CASGoogle Scholar
• 108  Nair SK, Morse M, Boczkowski D et al.: Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann. Surg.235(4),540–549 (2002).
  MedlineGoogle Scholar
• 109  Muller MR, Tsakou G, Grunebach F, Schmidt SM, Brossart P: Induction of chronic lymphocytic leukemia (CLL)-specific CD4^- and CD8-mediated T-cell responses using RNA-transfected dendritic cells. Blood103(5),1763–1769 (2004).
  MedlineGoogle Scholar
• 110  Nencioni A, Muller MR, Grunebach F et al.: Dendritic cells transfected with tumor RNA for the induction of anti-tumor CTL in colorectal cancer. Cancer Gene Ther.10(3),209–214 (2003).
  Medline CASGoogle Scholar
• 111  Milazzo C, Reichardt VL, Muller MR, Grunebach F, Brossart P: Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood101(3),977–982 (2003).
  Medline CASGoogle Scholar
• 112  Gilboa E, Vieweg J: Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol. Rev.199,251–263 (2004).
  Medline CASGoogle Scholar
• 113  Heiser A, Maurice MA, Yancey DR, Coleman DM, Dahm P, Vieweg J: Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res.61(8),3388–3393 (2001).
  Medline CASGoogle Scholar
• 114  Strobel I, Berchtold S, Gotze A, Schulze U, Schuler G, Steinkasserer A: Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes. Gene Ther.7(23),2028–2035 (2000).
  Medline CASGoogle Scholar
• 115  Koido S, Kashiwaba M, Chen D, Gendler S, Kufe D, Gong J: Induction of anti-tumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J. Immunol.165(10),5713–5719 (2000).
  Medline CASGoogle Scholar
• 116  Heiser A, Coleman D, Dannull J et al.: Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invest.109(3),409–417 (2002).
  Medline CASGoogle Scholar
• 117  Shortman K, Lahoud MH, Caminschi I: Improving vaccines by targeting antigens to dendritic cells. Exp. Mol. Med.41(2),61–66 (2009).
  Medline CASGoogle Scholar
• 118  Tacken PJ, Torensma R, Figdor CG: Targeting antigens to dendritic cellsin vivo. Immunobiology211(6–8),599–608 (2006).
  Medline CASGoogle Scholar
• 119  Jinushi M, Hodi FS, Dranoff G: Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. Immunol. Rev.222,287–298 (2008).
  Medline CASGoogle Scholar
• 120  Jinushi M, Tahara H: Cytokine gene-mediated immunotherapy: current status and future perspectives. Cancer Sci.100(8),1389–1396 (2009).
  Medline CASGoogle Scholar
• 121  Luiten RM, Kueter EW, Mooi W et al.: Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J. Clin. Oncol.23,8978–8991 (2005).
  Medline CASGoogle Scholar
• 122  Small EJ, Nemunaitis J, Marshall F et al.: Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin. Cancer Res.13,1883–3891 (2007).
  MedlineGoogle Scholar
• 123  Higano CS: Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer113,975–984 (2008).
  Medline CASGoogle Scholar
• 124  Filipazzi P, Valenti R, Huber V et al.: Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based anti-tumor vaccine. J. Clin. Oncol.25(18),2546–2553 (2007).
  Medline CASGoogle Scholar
• 125  Sica A, Bronte V: Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest.117(5),1155–1166 (2007).
  Medline CASGoogle Scholar
• 126  Van Kooyk Y: C-type lectins on dendritic cells: key modulators for the induction of immune responses. Biochem. Soc. Trans.36(Pt 6),1478–1481 (2008).
  Medline CASGoogle Scholar
• 127  Caminschi I, Proietto AI, Ahmet F et al.: The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. Blood112(8),3264–3273 (2008).
  Medline CASGoogle Scholar
• 128  Carter RW, Thompson C, Reid DM, Wong SY, Tough DF: Preferential induction of CD4⁺ T-cell responses through in vivo targeting of antigen to dendritic cell-associated C-type lectin-1. J. Immunol.177(4),2276–2284 (2006).
  Medline CASGoogle Scholar
• 129  Carter RW, Thompson C, Reid DM, Wong SY, Tough DF: Induction of CD8⁺ T-cell responses through targeting of antigen to dectin-2. Cell. Immunol.239(2),87–91 (2006).
  Medline CASGoogle Scholar
• 130  Boscardin SB, Hafalla JC, Masilamani RF et al.: Antigen targeting to dendritic cells elicits long-lived T-cell help for antibody responses. J. Exp. Med.203(3),599–606 (2006).
  Medline CASGoogle Scholar
• 131  Ramakrishna V, Treml JF, Vitale L et al.: Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T-cell responses via multiple HLA molecules. J. Immunol.172(5),2845–2852 (2004).
  Medline CASGoogle Scholar
• 132  Adema GJ, De Vries IJ, Punt CJ, Figdor CG: Migration of dendritic cell based cancer vaccines: in vivo veritas? Curr. Opin. Immunol.17(2),170–174 (2005).
  Medline CASGoogle Scholar
• 133  Verdijk P, Aarntzen EH, Lesterhuis WJ et al.: Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin. Cancer Res.15(7),2531–2540 (2009).▪ Demonstrates that although a small number of injected DCs end up within lymphoid tissues, these DCs have the capacity to activate immune responses.
  Medline CASGoogle Scholar
• 134  Schadendorf D, Ugurel S, Schuler-Thurner B et al.: Dacarbazine (Dtic) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized Phase III trial of the DC study group of the decog. Ann. Oncol.17(4),563–570 (2006).
  Medline CASGoogle Scholar
• 135  Higano CS, Schellhammer PF, Small EJ et al.: Integrated data from 2 randomized, double-blind, placebo-controlled, Phase III trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer115(16),3670–3679 (2009).
  Medline CASGoogle Scholar
• 136  Finn OJ, Forni G: Prophylactic cancer vaccines. Curr. Opin. Immunol.14(2),172–177 (2002).
  Medline CASGoogle Scholar
• 137  Jocham D, Richter A, Hoffmann L et al.: Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial. Lancet363(9409),594–599 (2004).
  Medline CASGoogle Scholar
• 138  Bronte V, Mocellin S: Suppressive influences in the immune response to cancer. J. Immunother.32(1),1–11 (2009).
  MedlineGoogle Scholar
• 139  Bennaceur K, Chapman J, Brikci-Nigassa L, Sanhadji K, Touraine JL, Portoukalian J: Dendritic cells dysfunction in tumour environment. Cancer Lett.272(2),186–196 (2008).
  Medline CASGoogle Scholar
• 140  Aptsiauri N, Cabrera T, Mendez R, Garcia-Lora A, Ruiz-Cabello F, Garrido F: Role of altered expression of HLA class I molecules in cancer progression. Adv. Exp. Med. Biol.601,123–131 (2007).
  MedlineGoogle Scholar
• 141  Chang CC, Ogino T, Mullins DW et al.: Defective human leukocyte antigen class I-associated antigen presentation caused by a novel b2-microglobulin loss-of-function in melanoma cells. J. Biol. Chem.281(27),18763–18773 (2006).
  Medline CASGoogle Scholar
• 142  Blank C, Gajewski TF, Mackensen A: Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother54(4),307–314 (2005).
  Medline CASGoogle Scholar
• 143  Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N: Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA99(19),12293–12297 (2002).
  Medline CASGoogle Scholar
• 144  Strome SE, Dong H, Tamura H et al.: B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res.63(19),6501–6505 (2003).
  Medline CASGoogle Scholar
• 145  Blank C, Kuball J, Voelkl S et al.: Blockade of PD-L1 (B7-H1) augments human tumor-specific T-cell responses in vitro. Int. J. Cancer119(2),317–327 (2006).
  Medline CASGoogle Scholar
• 146  Berger R, Rotem-Yehudar R, Slama G et al.: Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res.14(10),3044–3051 (2008).
  Medline CASGoogle Scholar
• 147  Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP: Blockade of CTLA-4 on both effector and regulatory T-cell compartments contributes to the anti-tumor activity of anti-CTLA-4 antibodies. J. Exp. Med. (2009).
  MedlineGoogle Scholar
• 148  Yuan J, Gnjatic S, Li H et al.: CTLA-4blockade enhances polyfunctional NY-ESO-1 specific T-cell responses in metastatic melanoma patients with clinical benefit. Proc. Natl Acad. Sci. USA105(51),20410–20415 (2008).
  Medline CASGoogle Scholar
• 149  O’day SJ, Hamid O, Urba WJ: Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer110(12),2614–2627 (2007).
  MedlineGoogle Scholar
• 150  Gilboa E: Knocking the SOCS1 off dendritic cells. Nat. Biotechnol.22(12),1521–1522 (2004).
  Medline CASGoogle Scholar
• 151  Croker BA, Kiu H, Nicholson SE: SOCS regulation of the JAK/STAT signalling pathway. Semin. Cell Dev. Biol.19(4),414–422 (2008).
  Medline CASGoogle Scholar
• 152  Shen L, Evel-Kabler K, Strube R, Chen SY: Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat. Biotechnol.22(12),1546–1553 (2004).
  Medline CASGoogle Scholar
• 153  Evel-Kabler K, Song XT, Aldrich M, Huang XF, Chen SY: SOCS1 restricts dendritic cells’ ability to break self tolerance and induce anti-tumor immunity by regulating IL-12 production and signaling. J. Clin. Invest.116(1),90–100 (2006).
  Medline CASGoogle Scholar
• 154  Cohen N, Mouly E, Hamdi H et al.: Gilz expression in human dendritic cells redirects their maturation and prevents antigen-specific T lymphocyte response. Blood107(5),2037–2044 (2006).
  Medline CASGoogle Scholar
• 155  Berrebi D, Bruscoli S, Cohen N et al.: Synthesis of glucocorticoid-induced leucine zipper (GILZ) by macrophages: an anti-inflammatory and immunosuppressive mechanism shared by glucocorticoids and IL-10. Blood101(2),729–738 (2003).
  Medline CASGoogle Scholar
• 156  Foss F: Clinical experience with denileukin diftitox (ONTAK). Semin. Oncol.33(1 Suppl. 3),S11–S16 (2006).
  Medline CASGoogle Scholar
• 157  Liu JY, Wu Y, Zhang XS et al.: Single administration of low dose cyclophosphamide augments the anti-tumor effect of dendritic cell vaccine. Cancer Immunol. Immunother.56(10),1597–1604 (2007).
  Medline CASGoogle Scholar
• 158  Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S: Stimulation of CD25⁺CD4⁺ regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol.3(2),135–142 (2002).
  Medline CASGoogle Scholar
• 159  Ko K, Yamazaki S, Nakamura K et al.: Treatment of advanced tumors with agonistic anti-gitr mab and its effects on tumor-infiltrating 3⁺CD25⁺CD4⁺ regulatory T cells. J. Exp. Med.202(7),885–891 (2005).
  Medline CASGoogle Scholar
• 160  Cohen AD, Diab A, Perales MA et al.: Agonist anti-GITR antibody enhances vaccine-induced CD8⁺ T-cell responses and tumor immunity. Cancer Res.66(9),4904–4912 (2006).
  Medline CASGoogle Scholar
• 161  Vicari AP, Chiodoni C, Vaure C et al.: Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J. Exp. Med.196(4),541–549 (2002).
  Medline CASGoogle Scholar
• 162  Fujita T, Teramoto K, Ozaki Y et al.: Inhibition of transforming growth factor-β-mediated immunosuppression in tumor-draining lymph nodes augments anti-tumor responses by various immunologic cell types. Cancer Res.69(12),5142–5150 (2009).
  Medline CASGoogle Scholar
• 163  Lopez MN, Pereda C, Segal G et al.: Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor β-expressing T cells. J. Clin. Oncol.27(6),945–952 (2009).
  Medline CASGoogle Scholar
• 164  Wang C, Lin GH, Mcpherson AJ, Watts TH: Immune regulation by 4-1-βB and 4-1-βBL: complexities and challenges. Immunol. Rev.229(1),192–215 (2009).
  Medline CASGoogle Scholar
• 165  May KF Jr, Chen L, Zheng P, Liu Y: Anti-4-1-βB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8⁺ T cells. Cancer Res.62(12),3459–3465 (2002).
  Medline CASGoogle Scholar
• 166  Murillo O, Dubrot J, Palazon A et al.: in vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb. Eur. J. Immunol.39(9),2424–2436 (2009).
  Medline CASGoogle Scholar
• 167  Kocak E, Lute K, Chang X et al.: Combination therapy with anti-CTL antigen-4 and anti-4-1-βB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res.66(14),7276–7284 (2006).
  Medline CASGoogle Scholar
• 168  Hanks BA, Jiang J, Singh RA et al.: Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo. Nat. Med.11(2),130–137 (2005).
  Medline CASGoogle Scholar
• 169  Lapteva N, Seethammagari MR, Hanks BA et al.: Enhanced activation of human dendritic cells by inducible CD40 and toll-like receptor-4 ligation. Cancer Res.67(21),10528–10537 (2007).
  Medline CASGoogle Scholar
• 170  Kutzler MA, Robinson TM, Chattergoon MA et al.: Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T-cell help. J. Immunol.175(1),112–123 (2005).
  Medline CASGoogle Scholar
• 171  Klebanoff CA, Finkelstein SE, Surman DR et al.: IL-15 enhances the in vivo anti-tumor activity of tumor-reactive CD8⁺ T cells. Proc. Natl Acad. Sci. USA101(7),1969–1974 (2004).
  Medline CASGoogle Scholar
• 172  Teague RM, Sather BD, Sacks JA et al.: Interleukin-15 rescues tolerant CD8⁺ T cells for use in adoptive immunotherapy of established tumors. Nat. Med.12(3),335–341 (2006).
  Medline CASGoogle Scholar
• 173  Schluns KS, Kieper WC, Jameson SC, Lefrancois L: Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat. Immunol.1(5),426–432 (2000).
  Medline CASGoogle Scholar
• 174  Rosenberg SA, Sportes C, Ahmadzadeh M et al.: IL-7 administration to humans leads to expansion of CD8⁺ and CD4⁺ cells but a relative decrease of CD4⁺ T-regulatory cells. J. Immunother.29(3),313–319 (2006).
  Medline CASGoogle Scholar
• 175  Minkis K, Kavanagh DG, Alter G et al.: Type 2 bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells. Cancer Res.68(22),9441–9450 (2008).
  Medline CASGoogle Scholar
• 176  Czerniecki BJ, Koski GK, Koldovsky U et al.: Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res.67(4),1842–1852 (2007).
  Medline CASGoogle Scholar
• 177  Adams S, O’neill DW, Nonaka D et al.: Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J. Immunol.181(1),776–784 (2008).
  Medline CASGoogle Scholar
• 178  Speiser DE, Lienard D, Rufer N et al.: Rapid and strong human CD8⁺ T-cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest.115(3),739–746 (2005).
  Medline CASGoogle Scholar
• 179  Warger T, Osterloh P, Rechtsteiner Get al.: Synergistic activation of dendritic cells by combined toll-like receptor ligation induces superior CTL responses in vivo. Blood108(2),544–550 (2006).
  Medline CASGoogle Scholar
• 180  Vandepapeliere P, Horsmans Y, Moris P et al.: Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T-cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine26(10),1375–1386 (2008).
  Medline CASGoogle Scholar
• 181  Longhi MP, Trumpfheller C, Idoyaga J et al.: Dendritic cells require a systemic type I interferon response to mature and induce CD4⁺ Th1 immunity with poly IC as adjuvant. J. Exp. Med.206(7),1589–1602 (2009).
  Medline CASGoogle Scholar
• 182  Reed SG, Bertholet S, Coler RN, Friede M: New horizons in adjuvants for vaccine development. Trends Immunol.30(1),23–32 (2009).
  Medline CASGoogle Scholar
• 183  Sharp FA, Ruane D, Claass B et al.: Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc. Natl Acad. Sci. USA106(3),870–875 (2009).
  Medline CASGoogle Scholar
• 184  Baumgaertner P, Rufer N, Devevre E et al.: ex vivo detectable human CD8 T-cell responses to cancer-testis antigens. Cancer Res.66(4),1912–1916 (2006).
  Medline CASGoogle Scholar
• 185  Diefenbach CS, Gnjatic S, Sabbatini P et al.: Safety and immunogenicity study of NY-ESO-1-β peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin. Cancer Res.14(9),2740–2748 (2008).
  Medline CASGoogle Scholar
• 186  Fourcade J, Kudela P, Andrade Filho PAet al.: Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8⁺ T cells in melanoma patients. J. Immunother.31(8),781–791 (2008).
  Medline CASGoogle Scholar
• 187  Marshall JL, Gulley JL, Arlen PM et al.: Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J. Clin. Oncol.23(4),720–731 (2005).
  Medline CASGoogle Scholar
• 188  Marshall JL, Hoyer RJ, Toomey MA et al.: Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J. Clin. Oncol.18(23),3964–3973 (2000).
  Medline CASGoogle Scholar
• 189  Dhodapkar MV: Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges. Front. Biosci.14,796–807 (2009).
  Medline CASGoogle Scholar
• 190  Chang DH, Osman K, Connolly J et al.: Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J. Exp. Med.201(9),1503–1517 (2005).
  Medline CASGoogle Scholar
• 191  Aquino A, Formica V, Prete SP et al.: Drug-induced increase of carcinoembryonic antigen expression in cancer cells. Pharmacol. Res.49(5),383–396 (2004).
  Medline CASGoogle Scholar
• 192  Correale P, Aquino A, Giuliani A et al.: Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro. Int. J. Cancer104(4),437–445 (2003).
  Medline CASGoogle Scholar
• 193  Lu W, Arraes LC, Ferreira WT, Andrieu JM: Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat. Med.10(12),1359–1365 (2004).▪▪ DC vaccine against HIV elicits T-cell responses that correlate with decreasedviral loads.
  Medline CASGoogle Scholar
• 201  List of clinical trials for antigen-pulsed DCs. www.clinicaltrials.gov
  Google Scholar
• 202  List of DC-based vaccine clinical trials. www.mmri.mater.org.au
  Google Scholar